The MISTIK project aims at clinically validating the technique of oral anticancer drugs determination by volumetric absorptive micro-sampling and at comparing the results to measurements performed on venous samples.
The International recommendations for the validation of DBS-based methods will be applied (Capiau et al, TDM, 2019) by including 40 patients per molecule of interest. Nine drugs will be monitored : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinib. Two samples will be collected from each patient, one by venous sampling and the second at the same time (approximately) using a capillary blood sample derived from a finger prick.
Study Type
OBSERVATIONAL
Enrollment
360
Measurement of anti-cancer drug concentrations using volumetric absorptive micro-sampling (VAMS) and venous blood sample
Centre Eugène Marquis Unicancer
Rennes, France
RECRUITINGRennes University Hospital
Rennes, France
RECRUITINGInstitut de cancérologie Strasbourg Europe
Strasbourg, France
RECRUITINGComparison of venous blood vs VAMS concentrations
Comparison of drug concentrations measured from the venous blood samples with concentrations measured from VAMS
Time frame: 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.